利安隆: 董事会决议公告

Meeting Details - The second meeting of the fifth board of directors of Tianjin Lianlong New Materials Co., Ltd. was held on August 17, 2025, via telephone and email notifications [1] - All 7 directors attended the meeting, which was chaired by Chairman Li Haiping, and the meeting procedures complied with relevant laws and regulations [1] Financial Reporting - The board confirmed that the 2025 semi-annual report and its summary were prepared and reviewed in accordance with legal requirements, accurately reflecting the company's operational status for the first half of 2025 [2] - The voting results for the approval of the semi-annual report were unanimous, with 7 votes in favor and no opposition [2] Corporate Restructuring - The board approved the absorption merger of Tianjin Aoruifu Biopharmaceutical Co., Ltd. with Tianjin Aolifu Biotechnology Co., Ltd., which aims to optimize the company's equity structure and improve management efficiency [2][3] - The investment in Aoruifu will increase from 4 million yuan to 6.5 million yuan, raising the ownership stake to 50.71%, maintaining Aoruifu as a subsidiary [3] Financing Strategy - The board agreed to apply for the registration and issuance of medium-term notes totaling up to 2 billion yuan to enhance financing channels and optimize the financing structure [3][4] - The issuance plan requires approval from the shareholders' meeting and registration with the trading association, with the board authorized to handle related matters [4] Upcoming Shareholder Meeting - A third temporary shareholders' meeting is scheduled for September 15, 2025, to be conducted with both on-site and online voting [4]